Transcatheter radiofrequency ablation of the pulmonary veins. Cost-benefit ratio and socioeconomic and health care implications;Ablación transcateter por radiofrecuencia de las venas pulmonares. Relación coste-beneficio e implicaciones socio-económico-sanitarias

Investigacion Cardiovascular

Volumn 8, Issue 2, 2005, Pages 87-99

  Hernández Madrid, Antonio ^a   Escobar Cervantes, C ^b   Marin Marin I ^b   Bernal Morell, E ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FLECAINIDE;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIAGNOSTIC TEST; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH ECONOMICS; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PULMONARY VEIN; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; RISK REDUCTION; SOCIOECONOMICS; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 30944449645     PISSN: 11392096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. KANNEL W B, ABBOTT R D, SAVAGE D D, MCNAMARA P M. Epidemiologic features of atrial fibrillation: the Framingham study. N Engl J Med. 1982; 306: 1018-1022.
2. KRAHN A D, MANFREDA J, TATE R B, MATHEWSON FAL, CUDDY T E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med. 1995; 98: 476-484.
3. PSATY B M, MANOLIO T A, KULLER L H, KRONMAL R A, CUSHMAN M, FRIED L P et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997; 96: 2455-2461.
4. BIALY D, LEHMAN H, SCHUMACHER D N, STEINMAN R T, MEISSNER M D. Hospitalizacion for arrhythmias in the United States: importance of atrial fibrillation. J Am Coll Cardiol. 1992; 19:41a.
5. BENJAMIN E J, WOLF P A, D'AGOSTINO R B, SILBERSHATZ H, KANNEL W B, LÉVY D. Impact of atrial fibrillation on the risk of death. The Framingham study. Circulation. 1998; 98: 946-952.
6. WOLF P A, MITCHELL J J, BAKER C S, KANNELL W B, D'AGOSTINO R B. Impact of atrial fibrillation on mortality, stroke, and medical cost. Ann Intern Med. 1998; 58: 229-234.
7. WOLF P A, ABBOTT R D, KANNELW B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-988.
8. CAIRNS J A, CONNOLLY S J. Nonrheumatic atrial fibrillation: risk of stroke and role of antithrombotic therapy. Circulation. 1991; 84: 469-481.
9. PETERS K G, KIENZLE M G. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after retoration of sinus rhythm. Am J Med. 1988; 85: 242-244.
10. ALLESSIE M A. Atrial electrophysiological remodeling: another vicious circle? J Cardiovasc Electrophysiol. 1998; 9: 1378-1393.
11. WIJFFELS MCEF, KIRCHHOF CJHJ, DORLAND R, ALLESSIE M A, BEGETS A F. A study in awake chronically instrumented goats. Circulation. 1995; 92: 1954-1968.
12. HAÏSSAGUERRE M, JAÏS P, SHAH D C, TAKAHASHI A, HOCINI M, QUINIOU G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998; 339: 659-666.
13. WYSE D G, WALDO A L, DIMARCO J P, DOMANSKI M J, ROSENBERG Y, SCHRON E B, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347:1825-33.
14. HOHNLOSER S H, KUCK K H, LILIENTHAL J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000; 356: 1789-94
15. VAN GELDER I C, HAGENS V E, BOSKER H A, KINGMA J H, KAMP O, KINGMA T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347: 1834-40.
16. GUERRA P G, LESH M D. The role of nonpharmacologic therapies for the treatment of atrial fibrillation. J Cardiovasc Electrophysiol. 1999; 10: 450-460.
17. SAVALIEVA I, CAMM A J. Atrial fibrillation and heart failure: natural history and pharmacologiacal treatment. Europace. 2004; 5: S5-S19.
18. BLOOM H L. Concise review of atrial fibrillation: treatment update considerations in light of AFFIRM and RACE. Clin. Cardiol. 2004; 27: 495-500.
19. ALMENDRAL J, VILLACASTÍN J, ARENAL A, ORTIZ M, MORRIS R, CASTELLANOS P et al. Tratamiento eléctrico de la fibrilación auricular. Rev Esp Cardiol. 1996; 49 (Supl 2): 50-54.
20. VAN DEN BERG M P, TUINENBURG A E, VAN VELDHUISEN D J, DE KAM P J, CRIJNS H J. Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. Int J Cardiol. 1998; 63: 63-70.
21. ATWOOD J E, MYERS J N, SULLIVAN M J, FORBES S M, SANDHU S, CALLAHAM P et al. The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation. Am Heart J. 1989; 118: 913-918.
22. GOSSELINK A T, CRIJNS H J, VAN DEN BERG M P, VAN DEN BROEK S A, HILLEGE H, LANDSMAN M L et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J. 1994; 72: 161-166.
23. COPLEN S E, ANTMAN E M, BERLIN J A, HEWITT P, CHALMERST C. Efficacy and safety of quinicline therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990; 82: 1106-16.
24. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrythmia suppression after myocardial infarction. The Cardiac Arrythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989; 321: 406-12.
25. JULIAN D G, CAMM A J, FRANGIN G, JANSE M J, MUNOZ A, SCHWARTZ P J, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997; 349: 667-74.
26. CAIRNS J A, CONNOLLY S J, ROBERTS R, GENT M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet. 1997; 349: 675-82.
27. ROY D, TALAJIC M, DORIAN P, CONNOLLY S, EISENBERG M J, GREEN M, et al. Amiodarone to prevent recurrence of atrial fibrillation. CanadianTrial of Atrial Fibrillation Investigators. N Engl J Med. 2000; 342: 913-20.
28. PEDERSEN O D, BAGGER H, KØBER L, TORP-PEDERSEN C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999; 100: 376-380.
29. FORTUÑO M A, RAVASSA S, ETAYO J C, DIEZ J. Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats. Effects of AT1 blockade with losartan. Hypertension. 1998; 32: 280-286.
30. MADRID A H, BUENO M G, REBOLLO J M, MARIN I, PEÑA G, BERNAL E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. a prospective and randomized study. Circulation. 2002; 106: 331-336.
31. CABALLERO R, DELPÓN E, VALENZUELA C, LONGOBARDO M, TAMARGO J. Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents. Circulation. 2002; 101: 1199-1205.
32. MORENO I, CABALLERO R, GONZALEZ T, ARIAS C, VALENZUELA C, IRIEPA I, et al. Effects of irbersartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther. 2003; 304: 862-73.
33. DE SIMONE A, STABILE G, VITALE D F, TURCO P, DI STASIO M, PETRAZZUOLI F, et al. Pre-treatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol. 1999; 34: 810-4.
34. VAN NOORD T, VAN GELDER I C, TIELEMAN R G, BOSKER H A, TUINENBURG A E, VOLKERS C, et al. VERDICT: the verapamil versus digoxin cardioversion trial: a randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2001; 12: 766-769.
35. VILLACASTÍN J P. Ablación percutánea de fibrilación auricular. Buenas perspectivas. Rev Esp Cardiol. 2003; 56: 331-332.
36. SILVA R, MONT L, BERRUEZO A, FOSCH X, WAYAR L, ALVARENGA N, et al. Ablación por radiofrecuencia para el tratamiento de la fibrilación auricular focal a través de cartografía circunferencial y aislamiento segmentario de las venas pulmonares. Rev Esp Cardiol. 2003; 56: 361-367.
37. OLGIN J E, SIH H J. Ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 1997; 8: 1266-1268.
38. PAPPONE C, ROSANIO S, AUGELLO G, GALLUS G, VICEDOMINI G, MAZZONE P, et al. Mortaliyi, morbidity and quality of life after circumferential pulmonary vein ablation for atrial fibrillation. Outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003; 42: 185-197.
39. SUZUKI S, KASANUKI H. The influences of psychosocial aspects and anxiety symptoms quality of life of patients with arrhythmia: investigation in paroxysmal atrial fibrillation. Int J Behav Med. 2004; 11: 104-9.
40. ENGELMANN M, PEHRSON S. Quality of life in non-pharmacologic treatment of atrial fibrillation. Eur Heart J. 2003; 24: 1387-1400.
41. GRÖNEFELD G, LILIENTHAL J, KUCK K H, HOHNLOSER S H. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Eur heart J. 2003; 24: 1430-1436.
42. HAGENS V E, VERMEULEN K M, TENVERGERT E M, VAN VELDHUISEN D J, BOSKER H A, KAMP O, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation-results from the rate control versus electrical cardioversion (RACE) study. Eur Heart J. 2004; 25: 1542-1549.
43. TENG M P, CATHERWOOD L E, MELBY D P. Cost effectiveness of therapies for atrial fibrillation. A review. Pharmacoeconomics. 2000; 18: 317-33.
44. LE HEUZEY JY, PAZIAUD O, PIOT O, SAID M A, COPIE X, LAVERGNE T, GUIZE L. Cost of care distribution in atrial fibrillation patients: the COCAF study. American Heart J. 2004; 147: 121-126.